enter here
The Safety and Efficacy of Psilocybin in Participants With Treatment Resistant Depression
About the study
NCT Trial Number
NCT03775200
The drug being studied
Psilocybin
Sponsored by
COMPASS Pathways
Trial Start Date
Jan-19
About the participants
Age seeking
18 Years to 54 Years
gender
All
Primary condition of volunteers accepted
Depression
Accepts healthy volunteers?
No
The safety and efficacy of Psilocybin in Participants with Treatment Resistant Depression
Locations
United States, California
Kadima Neuropsychiatry Institute
La Jolla, California, United States, 92037
Contact: Olga Johnson
olgaJ@kadimanp.com
Altman Clinical and Translational Research Institute, University of California
San Diego, California, United States, 92093
Contact: Lauren Cardoso
PsilocybinStudy@health.ucsd.edu
Stanford Department of Psychiatry
Stanford, California, United States, 94305
Contact:
Jessica Hawkins
jhawk@stanford.edu
United States, Georgia
Mood and Anxiety Disorders Program Emory University School of Medicine
Atlanta, Georgia, United States, 30329
Contact: Tanja Mletzk tmletzk@emory.edu
United States, Maryland
Sheppard Pratt Health System
Baltimore, Maryland, United States, 21204
Contact: Kelsie J Kaier KKaier@sheppardpratt.org
United States, New York
New York State Psychiatric Institute
New York, New York, United States, 10032
Contact: Richard Key richard.key@nyspi.columbia.edu
United States, Texas
UT Center of Excellence on Mood Disorders, University of Texas Health Science Center
Houston, Texas, United States, 77054
Contact:Valeria Cuellar
Valeria.A.Cuellar@uth.tmc.edu